DDInter82 DDInter1376
Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Amoxapine {u} (Compound) resembles {v} (Compound) Chlordiazepoxide
Amoxapine {u} (Compound) resembles {v} (Compound) Lorazepam
Amoxapine {u} (Compound) binds {v} (Gene) HTR7
Amoxapine {u} (Compound) upregulates {v} (Gene) MSMO1
Amoxapine {u} (Compound) causes {v} (Side Effect) Flatulence
Amoxapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Amoxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dronabinol
Amoxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Amoxapine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Amoxapine {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Amoxapine (Compound) resembles Chlordiazepoxide (Compound)
Amoxapine (Compound) resembles Lorazepam (Compound)
Amoxapine (Compound) binds HTR7 (Gene)
Amoxapine (Compound) upregulates MSMO1 (Gene)
Amoxapine (Compound) causes Flatulence (Side Effect)
Amoxapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amoxapine may lead to a major life threatening interaction when taken with Macimorelin
Amoxapine may lead to a major life threatening interaction when taken with Anagrelide